PCRX

News Pacira stock downgraded amid eVenus approval concerns - Barclays By Investing.com - Investing.com

14d ago

News Pacira BioSciences' CFO Sold 12,941 Shares for $326,000 Before Its Q1 Earnings Release

32d ago

News Pacira outlines 2026 revenue guidance of $745M-$770M while advancing PCRX-201 Phase II milestones

32d ago

Insider trade Sale by Shawn Cross (Chief Financial Officer)

38d ago

Insider trade Sale by Shawn Cross (Chief Financial Officer)

39d ago

Insider trade Sale by Shawn Cross (Chief Financial Officer)

40d ago

Insider trade Sale by Jonathan Slonin (Chief Medical Officer)

74d ago

Insider trade Sale by Mark Froimson

74d ago

News Pacira outlines $745M–$770M 2026 revenue target as 5x30 strategy drives margin and pipeline progress

95d ago

Insider trade Sale by Lauren Riker (Senior Vice President, Finance)

104d ago

Insider trade Sale by Kristen Williams (Chief Administrative Officer)

104d ago

News Pacira drops after adjusting 2025 revenue below consensus

144d ago

News Pacira reports preliminary FY25 revenue of $726.4M

144d ago

News Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

153d ago

News Pacira BioSciences Notified of Abbreviated New Drug Application Filing from Qilu Pharmaceutical (Hainan) Co., Ltd. for EXPAREL®

153d ago

News DOMA Perpetual Capital Management Announces Intent to Nominate Three Highly Qualified, Independent Director Candidates at 2026 Annual Meeting of Pacira BioSciences, Inc.

154d ago

News DOMA Perpetual Capital to offer nominees for Pacira BioSciences board

154d ago

Scanner Unusual volume (z=3.0)

160d ago

Scanner Unusual volume (z=3.2)

162d ago

Scanner Unusual volume (z=3.2)

163d ago

Scanner Unusual volume (z=3.2)

164d ago